Showing results (281-290 of 304) with videos related to
Sort By:
Pageof 31
The Lancet. Oncology|November 12, 2022
Fluorouracil and dose-dense adjuvant chemotherapy in patients with early-stage breast cancer (GIM2): end-of-study results from a randomised, phase 3 trialLucia Del Mastro, Francesca Poggio, Eva Blondeaux, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 30, 2016
Adjuvant Tamoxifen Plus Ovarian Function Suppression Versus Tamoxifen Alone in Premenopausal Women With Early Breast Cancer: Patient-Reported Outcomes in the Suppression of Ovarian Function TrialKarin Ribi, Weixiu Luo, Jürg Bernhard, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 26, 2026
Role of ctDNA in predicting the outcome of patients with hormone receptor-positive, HER2-negative advanced breast cancer treated with first-line ribociclib and letrozole: BioItaLEE trialGiampaolo Bianchini, Luca Malorni, Roberta Caputo, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 15, 2022
Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT TrialsOlivia Pagani, Barbara A Walley, Gini F Fleming, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2023
SNP of Aromatase Predict Long-term Survival and Aromatase Inhibitor Toxicity in Patients with Early Breast Cancer: A Biomarker Analysis of the GIM4 and GIM5 TrialsBenedetta Conte, Luca Boni, Giancarlo Bisagni, et al.The Journal of Pathology|November 3, 2020
CDKN1B mutation and copy number variation are associated with tumor aggressiveness in luminal breast cancerDavide Viotto, Francesca Russo, Ilaria Anania, et al.JAMA Network Open|November 3, 2025
Assessment of Adjuvant Endocrine Therapy With Ovarian Function Suppression by Breast Cancer IndexRuth M O'Regan, Yue Ren, Yi Zhang, et al.Critical Reviews in Oncology/Hematology|June 8, 2025
The evolving landscape of hormone receptor-positive/HER2-negative metastatic breast cancer (EVOLVE): An Italian Delphi consensus reportFederica Miglietta, Maria Grazia Razeti, Aldo Caltavituro, et al.Clinical Breast Cancer|December 26, 2018
A New Genetic Risk Score to Predict the Outcome of Locally Advanced or Metastatic Breast Cancer Patients Treated With First-Line Exemestane: Results From a Prospective StudySara Gagno, Mario Rosario D'Andrea, Mauro Mansutti, et al.The New England Journal of Medicine|June 3, 2014
Adjuvant exemestane with ovarian suppression in premenopausal breast cancerOlivia Pagani, Meredith M Regan, Barbara A Walley, et al.Pageof 31